Daniela Spano

Dr. Daniela Spano

Institute of Biochemistry and Cell Biology, National Research Council, Via Pietro Castellino 111, 80131 Naples, Italy
orcid

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2015 in Seminars in Cancer Biology
Verified
Journal Article
Open access
Wen G. JiangWen G. Jiang
Wen G. Jiang
ASA.J. Sanders
A.J. Sanders
Masaru KatohMasaru Katoh
Masaru Katoh
HUH. Ungefroren
H. Ungefroren
FGFrank Gieseler
Frank Gieseler
SDSantini Daniele
Santini Daniele
Cancer is a key health issue across the world, causing substantial patient morbidity and mortality. Patient prognosis is tightly linked with metastatic dissemination of the disease to distant sites, with metastatic diseases accounting for a vast percentage of cancer patient mortality. While advances in this area have been made, the process of cancer metastasis and the factors governing cancer spread and establishment at secondary locations is still poorly understood. The current article summarizes recent progress in this area of research, both in the understanding of the underlying biological processes and in the therapeutic strategies for the management of metastasis. This review lists the disruption of E-cadherin and tight junctions, key signaling pathways, including urokinase type plasminogen activator (uPA), phosphatidylinositol 3-kinase/v-akt murine thymoma viral oncogene (PI3K/AKT), focal adhesion kinase (FAK), β-catenin/zinc finger E-box binding homeobox 1 (ZEB-1) and transforming growth factor beta (TGF-β), together with inactivation of activator protein-1 (AP-1) and suppression of matrix metalloproteinase-9 (MMP-9) activity as key targets and the use of phytochemicals, or natural products, such as those from Agaricus blazei, Albatrellus confluens, Cordyceps militaris, Ganoderma lucidum, Poria cocos and Silybum marianum, together with diet derived fatty acids gamma linolenic acid (GLA) and eicosapentanoic acid (EPA) and inhibitory compounds as useful approaches to target tissue invasion and metastasis as well as other hallmark areas of cancer. Together, these strategies could represent new, inexpensive, low toxicity strategies to aid in the management of cancer metastasis as well as having holistic effects against other cancer hallmarks.

1 June 2012 in Seminars in Cancer Biology
Verified
Journal Article
Closed access
Daniela SpanoDaniela Spano
Daniela Spano
CHChantal Heck
Chantal Heck
PAPasqualino De Antonellis
Pasqualino De Antonellis
GCGerhard Christofori
Gerhard Christofori
FVFrancesca Valdora
Francesca Valdora

28 June 2009 in Nature Genetics
Verified
Journal Article
Closed access
PDF file
KSKlaus Schwarz
Klaus Schwarz
AIAchille Iolascon
Achille Iolascon
FVFatima Verissimo
Fatima Verissimo
NTNikolaus S Trede
Nikolaus S Trede
WHWyatt Horsley
Wyatt Horsley
HHHermann Heimpel
Hermann Heimpel

10 February 2012 in Clinical & Experimental Metastasis
Verified
Journal Article
Closed access
PDF file
Daniela SpanoDaniela Spano
Daniela Spano
FVFrancesca Valdora
Francesca Valdora

1 August 2007 in Hepatology
Verified
Journal Article
Open access
PDF file
Marcello PersicoMarcello Persico
Marcello Persico
Mario CapassoMario Capasso
Mario Capasso
EPEliana Persico
Eliana Persico
MSMonica Svelto
Monica Svelto
Roberta RussoRoberta Russo
Roberta Russo
AIAchille Iolascon
Achille Iolascon
The response to antiviral therapy is lower in hepatitis C virus (HCV) patients with genotype 1 than in those with genotype 2. Overexpression of the suppressor of cytokine signaling 3 (SOCS3) gene in liver tissue is associated with a poorer treatment outcome in patients with chronic hepatitis C viral genotype 1. Also, insulin resistance has been implicated in nonresponse to an anti-HCV treatment. To understand why HCV genotype 1 patients respond differently, we investigated SOCS3 gene expression, metabolic syndrome (MS), and the response to therapy in a cohort of patients with HCV-related hepatitis. A total of 198 patients (108 with genotype 1 and 90 with genotype 2) treated with pegylated interferon plus ribavirin were consecutively enrolled in the study. We measured SOCS3 expression in Epstein-Barr virus–transformed lymphoblastoid cell lines derived from peripheral lymphocytes of a subset of 130 patients. MS was more frequent in genotype 1 patients than in genotype 2 patients ( P < 0.01). Nonresponders ( P < 0.01), MS ( P < 0.001), and genotype 1 ( P < 0.001) were significantly related to SOCS3 overexpression. However, SOCS3 levels were higher in nonresponders also, regardless of the genotype ( P < 0.01). In a univariate analysis, the genotype ( P < 0.001), age ( P < 0.001), SOCS3 ( P < 0.001), and MS ( P < 0.001) were significantly related to the response to therapy. However, in a multivariate analysis, SOCS3 was the only independent predictor of the response (odds ratio = 6.7; P < 0.005). Conclusion: We speculate that SOCS3 expression per se may influence the response to antiviral therapy and that the genotype 1b virus might induce its up-regulation. This may account for the different responses to therapy between genotype 1–infected and genotype 2–infected patients. (HEPATOLOGY 2007.)

25 October 2017 in Scientific Reports
Verified
Journal Article
Open access
PDF file
GCGiuliana Catara
Giuliana Catara
GGGiovanna Grimaldi
Giovanna Grimaldi
LSLaura Schembri
Laura Schembri
Daniela SpanoDaniela Spano
Daniela Spano
GTGabriele Turacchio
Gabriele Turacchio
Daniela CordaDaniela Corda
Daniela Corda
Poly-ADP-ribose-polymerases (PARPs) 1 and 2 are nuclear enzymes that catalyze the poly-ADP-ribosylation of nuclear proteins transferring poly-ADP-ribose (PAR) polymers to specific residues. PARPs and PAR intervene in diverse functions, including DNA repair in the nucleus and stress granule assembly in the cytoplasm. Stress granules contribute to the regulation of translation by clustering and stabilizing mRNAs as well as several cytosolic PARPs and signaling proteins to modulate cell metabolism and survival. Our study is focused on one of these PARPs, PARP12, a Golgi-localized mono-ADP-ribosyltransferase that under stress challenge reversibly translocates from the Golgi complex to stress granules. PARP1 activation and release of nuclear PAR drive this translocation by direct PAR binding to the PARP12-WWE domain. Thus, PAR formation functionally links the activity of the nuclear and cytosolic PARPs during stress response, determining the release of PARP12 from the Golgi complex and the disassembly of the Golgi membranes, followed by a block in anterograde-membrane traffic. Notably, these functions can be rescued by reverting the stress condition (by drug wash-out). Altogether these data point at a novel, reversible nuclear signaling that senses stress to then act on cytosolic PARP12, which in turn converts the stress response into a reversible block in intracellular-membrane traffic.